story of the week
Efficacy of Donanemab in Patients With Early Symptomatic Alzheimer Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 2023 Jul 17;[EPub Ahead of Print], JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio, J Sparks, AM Wessels, S Shcherbinin, H Wang, ES Monkul Nery, EC Collins, P Solomon, S Salloway, LG Apostolova, O Hansson, C Ritchie, DA Brooks, M Mintun, DM SkovronskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.